Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | Director | June 13, 2025 | June 16, 2025 |
| LOEWS CORPL · Entity 3231 | Director | March 31, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date June 13, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2035-06-13 | Direct | 33,350 |
Reported balance
After 2025-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-13 · Grant · Acquired 33,350 · Balance 33,350 F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.
LOEWS CORP
Report date March 31, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,233 |
Reported balance
After 2026-03-31 transaction · row 1
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 235 · Balance 5,233 F1: Represents quarterly grant of common stock in respect of director compensation under the Loews Corporation 2025 Incentive Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents quarterly grant of common stock in respect of director compensation under the Loews Corporation 2025 Incentive Compensation Plan.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CANTEL MEDICAL CORP
Report date June 02, 2021 · Filed June 02, 2021
Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Disposition to issuer · Disposed 4,159 · Balance 0 F1: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration").
F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59.
Mirror Merger Sub 2, LLC
Report date March 01, 2021 · Filed March 03, 2021
Section 16 reporting ended · disclosed 2021-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-01 · Disposition to issuer · Disposed 2,477 · Balance 0 F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock. F2: This Deferred Stock Unit award, which was granted on November 2, 2020, was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $180,821.00. |
| Deferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2021-11-01 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-01 · Disposition to issuer · Disposed 3,363 · Balance 0 F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock. F3: This Deferred Stock Unit award, which was granted on November 1, 2019, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $245,499.00. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.90 · Expires 2023-11-01 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-01 · Disposition to issuer · Disposed 4,045 · Balance 0 F4: This option award, which was granted on November 1, 2013, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $125,799.50. |
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-01 · Disposition to issuer · Disposed 3,252 · Balance 0 F5: Each Phantom Stock Unit is the economic equivalent of one share of non-voting common stock. F6: This Phantom Stock Unit award, which was granted on November 1, 2017, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $237,396.00. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock.
F2: This Deferred Stock Unit award, which was granted on November 2, 2020, was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $180,821.00.
F3: This Deferred Stock Unit award, which was granted on November 1, 2019, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $245,499.00.
F4: This option award, which was granted on November 1, 2013, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $125,799.50.
F5: Each Phantom Stock Unit is the economic equivalent of one share of non-voting common stock.
F6: This Phantom Stock Unit award, which was granted on November 1, 2017, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $237,396.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2016 Filed Nov 7, 2016 13:21 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Disposition to issuerEaton Vance Corp. Non-voting Common Stock | 1,448 | $34.99 | $50,665.52 |
DisclosureSEC source: 0001225208-16-041250 · doc4.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 13:21 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Exercise / conversionEaton Vance Corp. Non-voting Common Stock | 1,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-041250 · doc4.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 18:42 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantPhantom Stock · Derivative | 2,009 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-041041 · doc4.xml · derivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,009 Underlying: Eaton Vance Corp. Non-voting Common Stock · 2,009 shares Expires 2018-11-01 F1 · security: Each share of Phantom Stock is the economic equivalent of one share of non-voting common stock. The shares of Phantom Stock become payable in cash at the earlier of the second anniversary of the grant date or the date of the non-employee director's termination. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 18:42 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantOption (right to buy) · Derivative | 11,777 | $0.00 Strike: $34.84 | $0.00 |
DisclosureSEC source: 0001225208-16-041041 · doc4.xml · derivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,777 Underlying: Eaton Vance Corp. Non-voting Common Stock · 11,777 shares Expires 2026-11-01 Read SEC document |
| September 30, 2016 Filed Oct 5, 2016 10:45 UTC | CANTEL MEDICAL CORP CMN · Entity 138805 | SaleCommon Stock | 1,453 | $77.56 | $112,697.59 |
DisclosureSEC source: 0000019446-16-000089 · edgar.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,424 F1 · price: The per share sale prices ranged from $77.55 to $77.65. Upon request by the Commission staff, the issuer or the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2016 Filed Aug 1, 2017 14:52 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | SaleCommon Stock, par value $.10 per share | 1,453 | $77.56 | $112,697.59 |
DisclosureSEC source: 0000019446-17-000025 · edgar.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,424 F1 · price: The per share sale prices ranged from $77.55 to $77.65. Upon request by the Commission staff, the issuer or the reporting person will provide full information regarding the number of shares wold at each separate price. Read SEC document |
| September 13, 2016 Filed Sep 14, 2016 17:08 UTC | LOEWS CORP L · Entity 3231 | GrantRestricted Stock Units · Derivative | 3.8 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-079751 · doc1.xml · derivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,527.8 Underlying: Common Stock · 3.8 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: Represents additional RSUs awarded to the Reporting Person on account of dividend equivalent rights associated with previously awarded RSUs (the "Previous RSUs"). F3 · derivative.exercise_date: These RSUs vest, and shares of the Issuer's common stock will be delivered to the Reporting Person, concurrently with Previous RSUs, subject to any election to defer delivery of shares made by the Reporting Person with respect to such Previous RSUs. F3 · derivative.expiration_date: These RSUs vest, and shares of the Issuer's common stock will be delivered to the Reporting Person, concurrently with Previous RSUs, subject to any election to defer delivery of shares made by the Reporting Person with respect to such Previous RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.